Scilex Holding Co (SCLX) · Nov 20, 2026 · Delisting
Nasdaq deficiency notice — MVLS below $35M for 30 consecutive business days; compliance deadline May 17, 2027
Scilex’s delisting filing gives the company until May 17, 2027 to restore Nasdaq compliance, adding pressure to an already cash-strained pain-drug business.
Scilex is a small commercial-stage pain-drug company trying to grow ZTlido while building early commercialization for GLOPERBA and ELYXYB; its latest reported balance sheet showed only about $0.6 million of cash and substantial dependence on future product sales and outside financing.
The filing adds a material listing problem, not a routine warning. Nasdaq says Scilex’s market value of listed securities stayed below the $35 million requirement for 30 straight business days, and the company also fails the alternative standards based on stockholders’ equity and net income.
The immediate trading impact is limited, but the operational clock has started. SCLX and SCLXW remain listed for now, while Nasdaq gives Scilex until May 17, 2027 to maintain at least $35 million of market value for 10 consecutive business days. 〔0〕 〔1〕
The deeper issue is that the filing confirms weak financial-market support around a business already short on liquidity. Scilex says it is only evaluating options to regain compliance and offers no committed transaction, operating improvement, or financing plan that would solve the deficiency. The company’s recent late filing for the September 30, 2026 quarter adds execution uncertainty, although the 8-K itself does not explain the cause.
Bottom line: This is a clear setback to Scilex’s current story: the company now must repair both its listing status and the financial conditions that caused the deficiency. The six-month window avoids an immediate delisting, but it does not remove the underlying pressure.
Regain Nasdaq compliance by May 17, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!